HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss

HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models.

Subsidie
€ 2.325.312
2022

Projectdetails

Introduction

HB-086 and HB-097 comprise our portfolio of therapeutic proteins. They are a family of growth factors with actions on sensory nerve cells and represent novel treatment approaches and a paradigm shift for medical treatment and prevention of severe, chronic conditions such as pain and hearing loss.

Mechanism of Action

The drug candidates target sensory nerve cells and their support cells in dorsal root ganglia and the inner ear. Evidence indicates a mode of action including:

  • Normalisation of impaired neuronal-glial crosstalk
  • Protection and regeneration of sensory nerve fibres

These mechanisms underpin increased peripheral afferent drive associated with chronic pain and apoptotic hearing loss.

Preclinical Data

Preclinical data confirm that:

  1. HB-086 completely abolishes pain sensation across different models.
  2. HB-097 preserves the sense of hearing in relevant models.

Dosing and Disease Progression

Importantly, documented prolonged effects warrant biweekly or monthly dosing and prevention of further disease progression.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.325.312
Totale projectbegroting€ 3.321.875

Tijdlijn

Startdatum1-6-2022
Einddatum31-5-2025
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • HOBA THERAPEUTICS APSpenvoerder

Land(en)

Denmark

Vergelijkbare projecten binnen EIC Accelerator

EIC Accelerator

PN6047 - a breakthrough treatment of neuropathic pain

PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.

€ 2.493.000
EIC Accelerator

Homeoproteins as novel therapies for neurodegenerative diseases

BrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function.

€ 2.500.000
EIC Accelerator

Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain

Sea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment.

€ 2.499.035
EIC Accelerator

A new life for people with severe disabling cluster headache: Neuromodulation therapy using safe, minimally-invasive simultaneous stimulation at the front and back of the head.

Salvia BioElectronics is developing PRIMUS, a dual-site peripheral nerve modulator for drug-refractory chronic headaches, aiming for market launch by 2026 after successful clinical trials.

€ 2.499.999
EIC Accelerator

Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)

GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.

€ 1.636.639

Vergelijkbare projecten uit andere regelingen

ERC Proof of...

Chronic PAIN eradiCAtion by taRgeting Schwann cElls

PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.

€ 150.000
ERC Proof of...

Pre-clinical development of a lentiviral gene therapy to treat hearing and balance loss in Usher 1B patients

The MY(O)SENSES project aims to develop and commercialize a novel lentiviral gene therapy for Usher syndrome, targeting hearing loss and vertigo to improve patient outcomes.

€ 150.000
ERC Advanced...

Molecules for Nociceptor Force Transduction

This project aims to identify and target specific molecules involved in nociceptor force transduction to develop new pain therapies.

€ 2.500.000
EIC Transition

Precision Hearing Diagnostics and Augmented-hearing Technologies

The project aims to develop a portable diagnostic device for cochlear synaptopathy and augmented-hearing technologies, transitioning innovative research into practical clinical applications.

€ 2.499.416
ERC Proof of...

Targeting peripheral nerves: a method for therapeutic modulation of inflammatory disease with non-invasive temporal interference

The project aims to develop a non-invasive, patch-based nerve stimulator using Temporal Interference to precisely target inflammation-regulating nerves, enhancing treatment for inflammatory diseases.

€ 150.000